Stock Track | Precigen Soars 13.87% in Pre-market on First Commercial Sales and Revenue Beat

Stock Track

Mar 26

Precigen's stock surged 13.87% during pre-market trading on Thursday, following the release of the company's full-year 2025 financial results.

The biopharmaceutical company reported its first commercial sales of PAPZIMEOS, the FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP). The drug generated $3.4 million in net product revenue in the fourth quarter of 2025, marking Precigen's successful transition from a clinical-stage to a commercial-stage company.

Full-year revenue reached $9.7 million, surpassing analyst expectations of $8.4 million. Investors reacted positively to the strong commercial momentum, with management noting a significant increase in demand for PAPZIMEOS in the first quarter of 2026. Additional positive developments include the assignment of a permanent J-code for streamlined reimbursement effective April 1, 2026, and a Marketing Authorization Application under review by the European Medicines Agency.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1164161985"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164161985\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1164161985?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 16:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164161985","market":"nz","top_or_hot":-1,"title":"Stock Track | Precigen Soars 13.87% in Pre-market on First Commercial Sales and Revenue Beat","media":"Stock Track","content":"<p>Precigen's stock surged 13.87% during pre-market trading on Thursday, following the release of the company's full-year 2025 financial results.</p><p>The biopharmaceutical company reported its first commercial sales of PAPZIMEOS, the FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP). The drug generated $3.4 million in net product revenue in the fourth quarter of 2025, marking Precigen's successful transition from a clinical-stage to a commercial-stage company.</p><p>Full-year revenue reached $9.7 million, surpassing analyst expectations of $8.4 million. Investors reacted positively to the strong commercial momentum, with management noting a significant increase in demand for PAPZIMEOS in the first quarter of 2026. Additional positive developments include the assignment of a permanent J-code for streamlined reimbursement effective April 1, 2026, and a Marketing Authorization Application under review by the European Medicines Agency.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Precigen Soars 13.87% in Pre-market on First Commercial Sales and Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Precigen Soars 13.87% in Pre-market on First Commercial Sales and Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-26 16:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Precigen's stock surged 13.87% during pre-market trading on Thursday, following the release of the company's full-year 2025 financial results.</p><p>The biopharmaceutical company reported its first commercial sales of PAPZIMEOS, the FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP). The drug generated $3.4 million in net product revenue in the fourth quarter of 2025, marking Precigen's successful transition from a clinical-stage to a commercial-stage company.</p><p>Full-year revenue reached $9.7 million, surpassing analyst expectations of $8.4 million. Investors reacted positively to the strong commercial momentum, with management noting a significant increase in demand for PAPZIMEOS in the first quarter of 2026. Additional positive developments include the assignment of a permanent J-code for streamlined reimbursement effective April 1, 2026, and a Marketing Authorization Application under review by the European Medicines Agency.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGEN","symbol_name":"Precigen","start_time":0,"source_url":"","article_id":"1164161985","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164161985","pubTimestamp":1774512408,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Precigen's stock surged 13.87% during pre-market trading on Thursday, following the release of the company's full-year 2025 financial results.The biopharmaceutical company reported its first...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PGEN":"Precigen"},"translate_title":"股票追踪|Precigen盘前飙升13.87%，首次商业销售和营收超预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGEN":1},"content_text":"Precigen's stock surged 13.87% during pre-market trading on Thursday, following the release of the company's full-year 2025 financial results.The biopharmaceutical company reported its first commercial sales of PAPZIMEOS, the FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP). The drug generated $3.4 million in net product revenue in the fourth quarter of 2025, marking Precigen's successful transition from a clinical-stage to a commercial-stage company.Full-year revenue reached $9.7 million, surpassing analyst expectations of $8.4 million. Investors reacted positively to the strong commercial momentum, with management noting a significant increase in demand for PAPZIMEOS in the first quarter of 2026. Additional positive developments include the assignment of a permanent J-code for streamlined reimbursement effective April 1, 2026, and a Marketing Authorization Application under review by the European Medicines Agency.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}